OmniAb spotlights OmniUltra platform for radioligand therapy at San Diego summit

OmniAb spotlights OmniUltra platform for radioligand therapy at San Diego summit
OmniAb unveils OmniUltra in San Diego

OmniAb drew attention this week at the Targeted Radiopharmaceuticals Summit in San Diego, where engagement around Yasmina Abdiche's presentation was notably high.

The company introduced OmniUltra, its in vivo discovery platform focused on structured peptides designed to enable radioligand therapy and other applications. OmniAb outlined the platform's potential for advancing therapeutic development in targeted radiopharmaceuticals. The summit brought together key stakeholders in the industry to explore technological advances and new approaches in the evolving radiopharmaceuticals landscape.

OmniAb previously introduced the OmniUltra platform for in vivo structured peptide discovery at the Targeted Radiopharmaceuticals Summit US 2026 in San Diego. The company highlighted the platform's use in radioligand therapy applications. That presentation set the stage for further discussions on therapeutic innovation at this week's summit.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.